{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:27:33Z","timestamp":1781170053586,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-1015-0","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T00:17:53Z","timestamp":1464826673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Padmanabha D.","family":"Shenoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Bavaliya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Sashidharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveri","family":"Nalianda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreelakshmi","family":"Sreenath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,2]]},"reference":[{"issue":"4","key":"1015_CR1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/01.rhu.0000083860.27509.f1","volume":"9","author":"J Taylor","year":"2003","unstructured":"Taylor J, Bolster M. Bronchiolitis obliterans with organizing pneumonia associated with scleroderma and scleroderma spectrum diseases. J Clin Rheumatol. 2003;9(4):239\u201345.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"1015_CR2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0002-9343(69)90044-8","volume":"46","author":"W D\u2019Angelo","year":"1969","unstructured":"D\u2019Angelo W, Fries J, Masi A, Shulman L. Pathologic observations in systemic sclerosis (scleroderma). Am J Med. 1969;46(3):428\u201340.","journal-title":"Am J Med"},{"issue":"2","key":"1015_CR3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.healun.2009.07.025","volume":"29","author":"N Todd","year":"2010","unstructured":"Todd N, Lavania S, Park M, Iacono A, Franks T, Galvin J, et al. Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia. J Heart Lung Transplant. 2010;29(2):188\u201394.","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"1015_CR4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","volume":"81","author":"C Ferri","year":"2002","unstructured":"Ferri C, Valentini G, Cozzi F, Sebastini M, Michelassi C, La Montagna G, et al. Systemic sclerosis. Medicine. 2002;81(2):139\u201353.","journal-title":"Medicine"},{"issue":"1","key":"1015_CR5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1874306400802010039","volume":"2","author":"C Simeon-Aznar","year":"2008","unstructured":"Simeon-Aznar C, Fonollosa-Pl\u00e1 V, Tolosa-Vilella C, Selva-O\u2019 Callaghan A, Solans-Laqu\u00e9 R, Palliza E, et al. Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. TORMJ. 2008;2(1):39\u201345.","journal-title":"TORMJ"},{"issue":"25","key":"1015_CR6","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"D Tashkin","year":"2006","unstructured":"Tashkin D, Elashoff R, Clements P, Goldin J, Roth M, Furst D, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655\u201366.","journal-title":"N Engl J Med"},{"issue":"3","key":"1015_CR7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","volume":"46","author":"S Nihtyanova","year":"2007","unstructured":"Nihtyanova S, Brough G, Black C, Denton C. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2013a retrospective analysis. Rheumatology. 2007;46(3):442\u20135.","journal-title":"Rheumatology"},{"key":"1015_CR8","doi-asserted-by":"crossref","unstructured":"Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med. 2012;2012:143637. doi: 10.1155\/2012\/143637 .","DOI":"10.1155\/2012\/143637"},{"issue":"5","key":"1015_CR9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","volume":"40","author":"A Fischer","year":"2013","unstructured":"Fischer A, Brown K, Du Bois R, Frankel S, Cosgrove G, Fernandez-Perez E, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40(5):640\u20136.","journal-title":"J Rheumatol"},{"issue":"2","key":"1015_CR10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","volume":"133","author":"A Gerbino","year":"2008","unstructured":"Gerbino A, Goss C, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133(2):455\u201360.","journal-title":"Chest"},{"issue":"10","key":"1015_CR11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10067-010-1498-z","volume":"29","author":"A Koutroumpas","year":"2010","unstructured":"Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas L. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010;29(10):1167\u20138.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"1015_CR12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","volume":"45","author":"S Liossis","year":"2006","unstructured":"Liossis S, Bounas A, Andonopoulos A. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology. 2006;45(8):1005\u20138.","journal-title":"Rheumatology"},{"issue":"1","key":"1015_CR13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","volume":"130","author":"J Swigris","year":"2006","unstructured":"Swigris J, Olson A, Fischer A, Lynch D, Cosgrove G, Frankel S, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30\u20136.","journal-title":"Chest"},{"issue":"1","key":"1015_CR14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rmed.2007.07.021","volume":"102","author":"A Zamora","year":"2008","unstructured":"Zamora A, Wolters P, Collard H, Connolly M, Elicker B, Webb W, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102(1):150\u20135.","journal-title":"Respir Med"},{"issue":"2","key":"1015_CR15","first-page":"287","volume":"25","author":"M Vanthuyne","year":"2007","unstructured":"Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol. 2007;25(2):287\u201392.","journal-title":"Clin Exp Rheumatol"},{"key":"1015_CR16","first-page":"S42","volume":"21","author":"TA Medsger","year":"2003","unstructured":"Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W, et al. Assessment of severity and prognosis in SSc. Clin Exp Rheumatol. 2003;21:S42\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"1015_CR17","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.rmed.2007.03.012","volume":"101","author":"H Collard","year":"2007","unstructured":"Collard H, Loyd J, King T, Lancaster L. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med. 2007;101(9):2011\u20136.","journal-title":"Respir Med"},{"issue":"6","key":"1015_CR18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/BOR.0b013e3283126985","volume":"20","author":"K Antoniou","year":"2008","unstructured":"Antoniou K, Wells A. Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol. 2008;20(6):686\u201391.","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"1015_CR19","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","volume":"176","author":"D Tashkin","year":"2007","unstructured":"Tashkin D, Elashoff R, Clements P, Roth M, Furst D, Silver R, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2\u00a0years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026\u201334.","journal-title":"Am J Respir Crit Care Med"},{"key":"1015_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/143637","volume":"2012","author":"A Tzouvelekis","year":"2012","unstructured":"Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med. 2012;2012:1\u20137.","journal-title":"Pulm Med"},{"issue":"2","key":"1015_CR21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/ard.62.2.97","volume":"62","author":"V Steen","year":"2003","unstructured":"Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003;62(2):97\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1015_CR22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2174\/157339710791330768","volume":"6","author":"D Khanna","year":"2010","unstructured":"Khanna D, Seibold J, Wells A, Distler O, Allanore Y, Denton C, et al. Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design. CRR. 2010;6(2):138\u201344.","journal-title":"CRR"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1015-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:53:15Z","timestamp":1567990395000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1015-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1015-0","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,2]]},"article-number":"123"}}